US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by HighTide Therapeutics Inc.
ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney Disease
October 22, 2026
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Tickers
HTTIF
ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801's Renoprotective Potential in Oral Presentation
June 04, 2026
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Tickers
HTTIF
Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont: Moving Beyond the "Blockbuster" Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach
April 01, 2026
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Tickers
HTTIF
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
October 30, 2025
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Tickers
HTTIF
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes
September 16, 2025
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Tickers
HTTIF
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
April 24, 2025
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open
March 03, 2025
From
HighTide Therapeutics Inc.
Via
ACN Newswire
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies
September 10, 2024
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
January 11, 2023
From
HighTide Therapeutics Inc.
Via
ACN Newswire
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA
April 14, 2025
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)
June 21, 2024
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
June 04, 2024
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
January 05, 2023
From
HighTide Therapeutics Inc.
Via
ACN Newswire
HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology
January 06, 2022
From
HighTide Therapeutics Inc.
Via
Business Wire
HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021
October 28, 2021
From
HighTide Therapeutics Inc.
Via
Business Wire
HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients
September 21, 2021
From
HighTide Therapeutics Inc.
Via
Business Wire
HighTide Therapeutics Announces the Presentation of Topline Results of Phase 2 Study of HTD1801 in PSC Patients at the International Liver Congress 2021
June 21, 2021
From
HighTide Therapeutics Inc.
Via
Business Wire
HighTide Announces NMPA Approval for HTD1801 Clinical Trial in China
May 27, 2021
From
HighTide Therapeutics Inc.
Via
Business Wire
HighTide to Present at the BofA Securities 2021 Health Care Conference
April 28, 2021
From
HighTide Therapeutics Inc.
Via
Business Wire
